Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-19
2005-07-19
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S002600, C514S020800, C514S023000, C514S042000, C514S832000, C514S866000
Reexamination Certificate
active
06919326
ABSTRACT:
Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.
REFERENCES:
patent: 3284531 (1966-11-01), Shaw et al.
patent: 3793187 (1974-02-01), Marx et al.
patent: 4171283 (1979-10-01), Nakashima et al.
patent: 4977287 (1990-12-01), Kakimoto et al.
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5827820 (1998-10-01), duMoulin
patent: 5855882 (1999-01-01), Li et al.
patent: 5861238 (1999-01-01), Li et al.
patent: 5868936 (1999-02-01), Ofsthun et al.
patent: 5891341 (1999-04-01), Li et al.
patent: 5962245 (1999-10-01), Li et al.
patent: 6727285 (2004-04-01), Haik, Jr.
patent: 2003/0143215 (2003-07-01), Miyata
patent: 0 242 855 (1987-10-01), None
patent: 0 222 313 (1989-05-01), None
patent: 2 316 852 (1989-05-01), None
patent: 0 339 496 (1989-11-01), None
patent: 0 359 112 (1990-03-01), None
patent: 0 433 679 (1991-06-01), None
patent: 0 474 874 (1992-03-01), None
patent: 62-142114 (1987-06-01), None
patent: 62-249908 (1987-10-01), None
patent: 62-249909 (1987-10-01), None
patent: 64-56615 (1989-03-01), None
patent: 64-83059 (1989-03-01), None
patent: 2-156 (1990-01-01), None
patent: 2-753 (1990-01-01), None
patent: 2-765 (1990-01-01), None
patent: 2-42053 (1990-02-01), None
patent: 2-62885 (1990-03-01), None
patent: 2-167264 (1990-06-01), None
patent: 3-148220 (1991-06-01), None
patent: 3-161441 (1991-07-01), None
patent: 3-204874 (1991-09-01), None
patent: 3-240725 (1991-10-01), None
patent: 3-261772 (1991-11-01), None
patent: 4-9375 (1992-01-01), None
patent: 4-502611 (1992-05-01), None
patent: 4-187158 (1992-07-01), None
patent: 4-308586 (1992-10-01), None
patent: 5-9114 (1993-01-01), None
patent: 5-105633 (1993-04-01), None
patent: 5-201993 (1993-08-01), None
patent: 5-505189 (1993-08-01), None
patent: 5-255130 (1993-10-01), None
patent: 5-310565 (1993-11-01), None
patent: 6-9380 (1994-01-01), None
patent: 6-135698 (1994-05-01), None
patent: 6-192089 (1994-07-01), None
patent: 6-206818 (1994-07-01), None
patent: 6-256280 (1994-09-01), None
patent: 6-507822 (1994-09-01), None
patent: 6-287179 (1994-10-01), None
patent: 6-287180 (1994-10-01), None
patent: 6-298737 (1994-10-01), None
patent: 6-305964 (1994-11-01), None
patent: 6-305969 (1994-11-01), None
patent: 7-500580 (1995-01-01), None
patent: 7-500811 (1995-01-01), None
patent: 7-503713 (1995-04-01), None
patent: 7-133264 (1995-05-01), None
patent: 7-196498 (1995-08-01), None
patent: 7-206838 (1995-08-01), None
patent: 7-247296 (1995-09-01), None
patent: 8-59485 (1996-03-01), None
patent: 8-131542 (1996-05-01), None
patent: 8-157473 (1996-06-01), None
patent: 9-40519 (1997-02-01), None
patent: 9-40626 (1997-02-01), None
patent: 59258 (1997-03-01), None
patent: 9-59233 (1997-03-01), None
patent: 9-124471 (1997-05-01), None
patent: 9-221427 (1997-08-01), None
patent: 9-241165 (1997-09-01), None
patent: 9-315960 (1997-12-01), None
patent: 63-19149 (1998-01-01), None
patent: 10-158244 (1998-06-01), None
patent: 10-158265 (1998-06-01), None
patent: 10-167965 (1998-06-01), None
patent: 10-175954 (1998-06-01), None
patent: 10-182-460 (1998-07-01), None
patent: WO 90/06102 (1990-06-01), None
patent: WO 91/11997 (1991-08-01), None
patent: WO 91/12800 (1991-09-01), None
patent: WO 92/11853 (1992-07-01), None
patent: WO 93/14750 (1993-08-01), None
patent: WO 93/19792 (1993-10-01), None
patent: WO 94/04520 (1994-03-01), None
patent: WO 96/02838 (1996-02-01), None
patent: WO 96/11196 (1996-04-01), None
patent: WO 93/04690 (1996-10-01), None
patent: WO 96/31537 (1996-10-01), None
patent: WO 97/09981 (1997-03-01), None
patent: WO 00/69466 (2000-11-01), None
patent: WO 01/24790 (2001-04-01), None
Tanaka, Yasushi et al., “Inhibitory Effect of Metformin on Formation of Advanced Glycation End Products” Current Therapeutic Research, Oct. 1997, 58 (10), 693-697.
Lo et al.,J. Biol. Chem.269(51)32299-32306 (1994).
Niquette et al.,J. Am. Water Works Assoc.90(1):96-97 (1998).
Tanaka et al.,Current Therapeutic Research58(10)693-7 (1997).
Combet et al. (2000) “Vascular Proliferation and Enhanced Expression of Endothelial Nitric Oxide Synthase in Human Peritoneum Exposed to Long-Term Peritoneal Dialysis.”J. Am. Soc. Nephrol., vol. 11:717-728.
Combet et al. (1999) “Regulation of Aquaporin-1 and Nitric Oxide Synthase Isoforms in a Rat Model of Acute Peritonitis.”J. Am. Soc. Nephrol., vol. 10:2185-2196.
Faller (1996) “Amino acid-based peritoneal dialysis solutions.”Kidney International, vol. 50(56):S-81-S-85.
Miyata et al. (2000) “Mechanism of the Inhibitory Effect of OPB-9195 [(±)-2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation End Product and Advanced Lipoxidation End Product Formation.”J>Am. Soc. Nephrol., vol. 11:1719-1725.
Miyata et al. (1996) “Accumulation of Albumin-Linked and Free-Form Pentosidine in the Circulation of Uremic Patients with End-Stage Renal Failure: Renal Implications in the Pathophysiology of Pentosidine.”Journal of the American Society of Nephrology, vol. 7(8):1198-1206.
Miyata et al. (1998) “Accumulation of Carbonyls Accelerates the Formation of Pentosidine, an Advanced Glycation End Product: Carbonyl Stress in Uremia.”J. Am. Soc. Nephrol., vol. 9:2349-2356.
Miyata et al. (1998) “Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia?”Kidney International, vol. 54:1290-1295.
Miyata et al. (1999) “Alterations in nonenzymatic biochemistry in uremia: Origin and signifiance of “carbonyl stress” in long-term uremic complications.”Kidney International, vol. 55:389-399.
Miyata et al. (1997) “Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.”Kidney International, vol. 51:1170-1181.
Nakayama et al. (1997) “Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.”Kidney International, vol. 51:182-186.
Wilkie et al. (1997) “Polyglucose Solutions in CAPD.”Peritoneal Dialysis International, vol. 17(2):S47-S50.
Yamada et al. (1994) “Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure.”Clinical Nephrology, vol. 42(6):354-361.
Niwa et al., “Modification of Beta2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum,”Kidney International49:861-867 (1996).
Miyata et al., “2-Isoproylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilde (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery; role of glycoxidation and lipoxidation reactions in vascular tissue damage.”FEBS Letters445(1):202-6 (1999).
Fishbane, et al., “Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.”Kidney International52(6):1645-50 (1997).
Feather et al., “The Use of Aminoguanidine to Trap and Measure Dicarbonyl Intermediates Produced During the Maillard Reaction.”ACM Symp Ser 631631:24-31 (1996).
Booth et al., “In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products
Bozicevic Karl
Bozicevic Field & Francis LLP
Kurakawa Kiyoshi
Lewis Patrick
Miyata Toshio
LandOfFree
Carbonyl-stress improving agent and peritoneal dialysate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbonyl-stress improving agent and peritoneal dialysate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbonyl-stress improving agent and peritoneal dialysate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378251